These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38876435)

  • 1. Cyclophosphamide in refractory autoimmune hepatitis and autoimmune hepatitis coexisting extrahepatic autoimmune disorders.
    Xiong A; Li S; Dou X; Yao Y
    Am J Med Sci; 2024 Nov; 368(5):446-454. PubMed ID: 38876435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis.
    Hanouneh M; Ritchie MM; Ascha M; Ascha MS; Chedid A; Sanguankeo A; Zein NN; Hanouneh IA
    Scand J Gastroenterol; 2019 Jan; 54(1):76-80. PubMed ID: 30650311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial.
    Stoelinga AEC; Tushuizen ME; van den Hout WB; Girondo MDMR; de Vries ES; Levens AD; Moes DAR; Gevers TJG; van der Meer S; Brouwer HT; de Jonge HJM; de Boer YS; Beuers UHW; van der Meer AJ; van den Berg AP; Guichelaar MMJ; Drenth JPH; van Hoek B;
    Trials; 2024 Jan; 25(1):61. PubMed ID: 38233878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
    Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
    De Lemos-Bonotto M; Valle-Tovo C; Costabeber AM; Mattos AA; Azeredo-da-Silva ALF
    Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):212-216. PubMed ID: 29227329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy.
    Than NN; Wiegard C; Weiler-Normann C; Füssel K; Mann J; Hodson J; Hirschfield GM; Lohse AW; Adams DH; Schramm C; Oo YH
    Scand J Gastroenterol; 2016 Mar; 51(3):329-36. PubMed ID: 26458216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
    Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Tushuizen ME; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Baven Pronk MAMC; Beuers U; van der Meer AJ; Gerven NMFV; Sijtsma MGM; van Eijck BC; van IJzendoorn MC; van Herwaarden M; van den Brand FF; Korkmaz KS; van den Berg AP; Guichelaar MMJ; Levens AD; van Hoek B; Drenth JPH;
    J Hepatol; 2024 Apr; 80(4):576-585. PubMed ID: 38101756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
    Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
    Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
    Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
    Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil.
    Liberal R; Gaspar R; Lopes S; Macedo G
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101487. PubMed ID: 32651078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases.
    Dan D; Fischer R; Adler S; Förger F; Villiger PM
    Swiss Med Wkly; 2014; 144():w14030. PubMed ID: 25341028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
    Chatur N; Ramji A; Bain VG; Ma MM; Marotta PJ; Ghent CN; Lilly LB; Heathcote EJ; Deschenes M; Lee SS; Steinbrecher UP; Yoshida EM
    Liver Int; 2005 Aug; 25(4):723-7. PubMed ID: 15998421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
    Hennes EM; Oo YH; Schramm C; Denzer U; Buggisch P; Wiegard C; Kanzler S; Schuchmann M; Boecher W; Galle PR; Adams DH; Lohse AW
    Am J Gastroenterol; 2008 Dec; 103(12):3063-70. PubMed ID: 18853972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
    Mok CC
    Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis.
    Lee YH; Song GG
    Pharmacology; 2022; 107(9-10):439-445. PubMed ID: 35609529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
    Wolf DC; Bojito L; Facciuto M; Lebovics E
    Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis.
    Ozaslan E; Efe C; Akbulut S; Purnak T; Savas B; Erden E; Altiparmak E
    Hepatogastroenterology; 2010; 57(99-100):441-6. PubMed ID: 20698205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.